e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Clinical management of interstitial lung diseases and vasculitis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Efficacy of inhaled N-acetylcystein in patients with interstitial pneumonia
R. Okuda, T. Ohba, T. Nishizawa, R. Kawabe, K. Honda, M. Amano, H. Matsushima (Saitama, Japan)
Source:
International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Session:
Clinical management of interstitial lung diseases and vasculitis
Session type:
Poster Discussion
Number:
4500
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Okuda, T. Ohba, T. Nishizawa, R. Kawabe, K. Honda, M. Amano, H. Matsushima (Saitama, Japan). LATE-BREAKING ABSTRACT: Efficacy of inhaled N-acetylcystein in patients with interstitial pneumonia. Eur Respir J 2014; 44: Suppl. 58, 4500
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
"Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease"
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy
Source: International Congress 2014 – ILDs 4
Year: 2014
The prognostic factor in patients with myositis-associated interstitial lung disease
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Rituximab in severe, treatment-refractory interstitial lung disease
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Clinical course and outcome of vasculitis related interstitial lung disease
Source: International Congress 2014 – ILDs 2
Year: 2014
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
The clinical features of 13 patients with interstitial pneumonia with positive anti-glycyl-tRNA synthetase autoantibodies
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Study of factors affecting mortality in ILD cases over 2 years
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Neoplasia in patients with ILD; shortened survival
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
OSA with intertitial lung diseases
Source: International Congress 2016 – Effect of sleep apnoea on life-span and comorbidities
Year: 2016
Safety and advantages of VATS biopsy in diagnosis of interstitial lung disease
Source: International Congress 2015 – Challenges in surgery for non-malignant disorders: pleural mediastinal and tracheal problems, congenital disorders
Year: 2015
LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept